Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?

• Главные авторы: Adkins EM (Автор), Nicholson L (Автор), Floyd D (Автор), Ratcliffe M (Автор), Chevrou-Severac H (Автор)
• Формат: ‌
• Опубликовано: Dove Medical Press, 2017-06-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Elizabeth M Adkins,1 Lindsay Nicholson,1 David Floyd,1 Mark Ratcliffe,1 Helene Chevrou-Severac2 1PHMR, London, UK; 2Takeda Pharmaceuticals AG, Zurich, Switzerland Abstract: Orphan drugs (ODs) are intended for the diagnosis, prevention, or treatment of rare diseases. Many cancer subtypes, including a...